Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
Retrieved on:
Tuesday, June 27, 2023
Manchester University NHS Foundation Trust, GSK, Montefiore Medical Center, CSE, University, Critical Care Medicine (journal), RCC, Drug discovery, AGN, NMDA, Brain, Merck & Co., USD, Chronic cough, GSK plc, Acquisition, Patient, Division, Respiratory Medicine, Internal medicine, NHS foundation trust, University of Manchester, Merck, IPF, Regulation of tobacco by the U.S. Food and Drug Administration, P2X3, Idiopathic pulmonary fibrosis, Food, Ifenprodil, Pharmaceutical industry, Bellús
Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signaling in the brain, suppressing the urge to cough.
Key Points:
- Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signaling in the brain, suppressing the urge to cough.
- Patients with IPF are usually excluded from trials in refractory chronic cough (“RCC”), and cough in this population is regarded as extremely difficult to treat.
- Algernon previously announced on January 14, 2022, that it had received positive feedback from the U.S. Food and Drug Administration at its pre-Investigational New Drug (pre-IND) meeting for its investigation of Ifenprodil solely for the treatment of chronic cough.
- She runs a multi-disciplinary research team whose focus is on understanding mechanisms underlying pathological cough and a regional clinical service seeing patients with refractory chronic cough.